Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study
Authors' conclusion
Our findings suggest that intensive glycemic control contributes to the prevention of major CAD events among ADVANCE participants with the Hp2-2 phenotype and no previous CVD and are in alignment with our hypothesis that intensive glycemic control may be beneficial in a subset of people with the Hp2-2 phenotype.
Study context
- Population
- People with T2D in the ADVANCE biomarker case-cohort study with haptoglobin phenotype measured; with Hp2–2 phenotype and withoutHp2–2 1,327 · with Hp2-2 phenotype 1,327 · without 2,077
- Comparison
- Intensive glycemic control vs standard therapy, by Hp2-2 phenotype
- Primary endpoint
- Major CAD events
Methodological detailscase-cohort biomarker study, weighted multivariable-adjusted Cox regression, prespecified stratifications by sex, race, previous cardiovascular disease (CVD), diabetes duration and HDL-C
- Case-cohort biomarker study
- Weighted multivariable-adjusted Cox regression
- Prespecified stratifications by sex, race, previous CVD, diabetes duration and HDL-C
Primary result
As reported in the abstract
Major CAD events, by Hp2-2 phenotype
Intensive glycemic control vs Standard therapyHazard ratio (95% CI)P value
Without Hp2-2 phenotype
1.04(0.82–1.32)
With Hp2-2 phenotype
0.84(0.63–1.14)
P = 0.27for interactionFurther findings
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| Major CAD events, Hp2-2 phenotype with no previous CVDLower CAD risk with intensive therapy | 0.47 (0.29–0.76) | P for interaction = 0.01 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study. Diabetes Care. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →